This activity is expired and is no longer available for CME credit.


Neovascular AMD: Impact of Dosing Regimens and Residual Retinal Fluid on Long-Term Outcomes

Author(s)/Faculty: Rishi P. Singh, MD; Nancy M. Holekamp, MD; Judy E. Kim, MD
Release Date: 6/16/2021Expiration Date: 6/15/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0
Content Type: LectureProvider:
Intravitreal therapy has rapidly evolved to become a mainstay of treatment for many retinal diseases and offers many patients delayed or arrested disease progression and the possibility of regaining lost vision. The discovery that intravitreal therapy can be effective in treating neovascular age-related macular degeneration (nAMD) has spurred further research exploring the outcomes of treatment regimens using this approach. Further, newer protocols that allow for longer intervals between treatment are now available and hold promise in lessening treatment burden. Yet ophthalmologists are challenged to select the most appropriate dosing regimen and are unsure of the effect of residual retinal fluid following treatment. In this continuing education activity, expert clinicians discuss the latest updates on treatment protocols, the impact of subtypes of retinal fluid, as well as an interesting case.